Thermo Fisher Scientific has launched a predictive assay that, it claims, can assess a drug candidate’s potential to cause liver damage earlier than traditional methods.
Agilent Technolgies, the Santa Clara, US-based scientific instrument manufacturer, has acquired instrument manufacturer and contract research organisation (CRO), Biocius Life Sciences, for an undisclosed amount.
South Korea's Samsung Group has announced plans to form a 'strategic partnership' with US contract research organisation (CRO), Quintiles, as it gears up to enter the biopharma market.
Tokyo, Japan-based digital imaging specialist, Fujifilm, has agreed a deal to buy US drug giant Merck and Co's BioManufacturing Network, including two biotech manufacturing plants.
Non-clinical CRO CIT will distribute Stemina’s hES-based toxicity testing platform to pharmaceutical and cosmetics developers in Europe under an agreement announced late last week.
Contract active pharmaceutical ingredient (API) maker Onyx Scientific has launched a range of novel amino acid derivatives for drug discovery and development projects.
Novasep and instrAction have partnered to develop improved methods for the production of taxane-based active pharmaceutical ingredients (API) citing growing demand for cancer treatments as key driver.
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
RecipharmCobra Biologics has received an EU patent for a genetic modification tech that allows antibiotic resistance genes to be removed after insertion is complete.
US contract research organisation (CRO) Parexel has cut its 2011 guidance, citing slower backlog conversion from projects generated by “strategic partnerships” as basis for the revision.
Oxford Biomedica has bought RecipharmCobra Biologics’ manufacturing facility in Oxford, UK, to reduce its reliance on third-party production of its gene delivery technology.
Pfizer’s Centres for Therapeutic Innovation (CTI) has teamed up with seven New York research hospitals to accelerate biomedical research into life-saving medicines, with a focus on biologics.
Genzyme will build a second manufacturing plant in Geel, Belgium to ensure it has the capacity to meet demand for its Pompe disease drugs Myozyme and Lumizyme.
French contract research organisation (CRO) CIT will work on in vitro toxicity testing for pharmaceutical and cosmetic ingredients as the newest member of the European “ScreenTox” network.
Merck plans to cash in on the biogenerics industry after forming a partnership with Parexel to develop copies of biologic drugs within its Merck BioVentures division.
Enlight Biosciences, a Boston, US-based drug discovery and development technologies company, has formed the new company, Entrega, which focuses on oral drug delivery techniques.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at BioDelivery Sciences, SOCMA and Sanofi-aventis.
Drug developers are “aggressively changing” research and development (R&D) methods in the pursuit of the next blockbuster, according to the Tufts Centre for the Study of Drug Development (Tufts CSDD).
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
Bayer HealthCare is investing €35m ($47m) in a new centre for the biotechnological production of ‘innovative’ pharmaceuticals to be used in clinical trials.
ProJect Pharmaceutics has opened its Munich headquarters and laboratory facilities in Martinsreid, Germany, beginning business operations to transform proteins, peptides and small molecules into novel drugs.
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
Advinus Therapeutics is to use Corning Epic label-free detection to provide clients in India and abroad with biologically relevant drug discovery data.
Lanxess has opened an ion exchange resin production facility in India to cater for growing pharmaceutical manufacturing sector demand for ultrapure water.
Recognition of glass vial quality issues is supporting interest in West’s analytical capabilities and Crystal Zenith (CZ) products, new sizes of which are being developed, said a company VP.
Quintiles and London Genetics will offer pharmacogenetics solutions to the biopharma industry after collaborating to help advance personalised medicine.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences.
German pharmaceutical giant Merck's life science division, EMD Millipore, has launched its 'single-use' Mobius 3L CellReady Bioreactor, for use in the development and optimisation of cell culture processes.
Merck Millipore says Gyros’ Gyrolab xP workstation will be a competitive advantage for its contract immunogenicity, pharmacokinetics and cGMP testing offering for the biopharmaceutical industry.
Crucell and Eden Biodesign have entered into an agreement that sees Eden become a provider of services of contract manufacturing services for Crucell's PER.C6 cell-line technology.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Lonza is seeing increased capacity utilisation and project pipelines in custom manufacturing but warned more stringent regulatory approval is creating volatility.
